Evidence map›Paper›PMID 33269066›Full record

ArticleWorld journal of diabetes2020

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review.

Li Zhang, Shuai Xue, Jie Hou, Guang Chen, Zhong-Gao Xu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Reduced abundance ofFrontiers in pharmacology · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Li ZhangDepartment of Nephrology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Shuai XueDepartment of Thyroid Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Jie HouDepartment of Nephrology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Guang ChenDepartment of Thyroid Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Zhong-Gao XuDepartment of Nephrology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China. nephrology_jdyy@hotmail.com.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is the main cause of chronic kidney disease and end-stage renal disease worldwide. Although available clinical trials have shown that endothelin receptor (ER) antagonists may be a novel and beneficial drug for DN, no consistent conclusions regarding their sufficient effectiveness and safety for patients with DN have been presented.

aimTo assess the effectiveness and safety of ER antagonists among patients with DN.

methodsThe EMBASE, PubMed, MEDLINE, Cochrane, and ClinicalTrials.gov databases were searched without any language restrictions. Relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences or standardized mean difference with 95%CIs for continuous data were calculated using Review Manager 5.3 software. Publication bias was assessed using Egger's test with Stata/SE software.

resultsWe enrolled seven studies with six data sets and 5271 participants. The ER antagonists group showed a significantly greater reduction in albuminuria and more patients with 40% reduction in urinary albumin-to-creatinine ratio than the control group (

conclusionER blockades combined with angiotensin converting enzyme inhibitor /angiotensin II type 1 receptor blockers may be an effective treatment to lower blood pressure and reduce proteinuria in DN with declined eGFR. However, attention should be given to adverse events, including cardiac failure, anemia, and hypoglycemia, as well as serious adverse events.

Indexed as

Diabetic nephropathyEndothelin receptorEndothelin receptor antagonistsEndothelin receptor blockadeMeta-analysisSystematic review

Identifiers

PMID33269066
PMCPMC7672789
OpenAlexW3108608800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.